A few weeks after selling off certain regional rights to monoclonal antibody (mAb) rademikibart, Connect Biopharma is back to share that the mid-stage asthma trial assessing the candidate has hit its ...
Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...
Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near- maximal responses achieved in ~90% of patients - - Rademikibart was well tolerated with safe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results